DocumentRX-2536
Issued
Read3 min

FDA Clears Two Tubeless Insulin Systems; Medtronic Buys Contego for $380M

FDA cleared tubeless insulin systems from Tandem and MiniMed, Medtronic agreed to buy Contego Medical for $380M, and CDER issued a new MAPP on clinical pharmacology review practices.

TAG K-1653 · 524 words on the filing

Recon: FDA approves Roche’s oral SERD for late-stage breast cancer; Lilly strikes up to $5.9B cancer deal with Stipple B
Recon: FDA approves Roche’s oral SERD for late-stage breast cancer; Lilly strikes up to $5.9B cancer deal with Stipple BBru-nO / pixabay

Summary of findings

  • Medtronic agreed to acquire Contego Medical for $380 million
  • FDA cleared tubeless insulin systems from both Tandem and Medtronic's MiniMed
  • CDER's OTS and OCP released a new MAPP on clinical pharmacology review of NDAs and BLAs
  • John Powers III was appointed permanent NIAID director
  • The U.S. lost measles-free status held for 26 years, Reuters reported

The FDA has cleared two tubeless insulin delivery systems in rapid succession, while Medtronic committed $380 million to acquire Contego Medical. The moves cap a busy stretch across pharma, medtech and regulatory affairs.

What did FDA clear this week?

Tandem Diabetes Care won FDA clearance for a tubeless automated insulin delivery system, MedTech Dive reported. Medtronic's MiniMed unit followed with its own FDA nod for a tubeless insulin pump. Both clearances advance the shift away from tethered pump hardware. For device makers, two clearances in one cycle signal intensified competition in the tubeless segment.

Medtronic did not stop at product news. The company agreed to buy Contego Medical, a vascular device developer, for $380 million. That figure roughly equals the cost of a mid-sized clinical program and marks Medtronic's latest bolt-on in cardiovascular intervention.

What is FDA changing on the review side?

FDA's Office of Translational Sciences and Office of Clinical Pharmacology, both under CDER, released a new manual of policies and procedures. The MAPP outlines good review practices for clinical pharmacology review of NDAs and BLAs. Sponsor teams should read it as the operative playbook for how OCP staff will assess pharmacokinetic and dose-response content in submissions. The takeaway: CDER has codified its clinical pharmacology review expectations in a single public document.

What happened in government and legal?

  • The White House appointed John Powers III as permanent director of NIAID, removing the acting designation he had carried. STAT and the New York Times reported the move.
  • Georgia, Kansas and Texas are weighing Medicaid expansion after midterm results shifted state politics, according to Politico.
  • A new Trump administration regulation targets what it calls fraudsters, but STAT reported all projected savings come from Medicare Advantage.
  • A federal judge issued a final ruling blocking a U.S. plan to limit visa length for graduate students and postdocs, a win for academic research staffing.
  • Reuters reported the U.S. must intensify vaccination efforts to regain its measles elimination status, lost after 26 years.

What moved in food safety and digital health?

A new study found genetic links between drug-resistant foodborne pathogens in humans, foods and animals, Food Safety Magazine reported. The findings strengthen the case for genomic surveillance across the farm-to-patient chain. Separately, Food Safety News covered countries working to resolve food safety trade disputes at a WTO meeting.

In digital health, patient data startup b.well launched new tools designed to make AI chatbots safer, Endpoints reported. The tools target the data-integrity layer beneath conversational health interfaces.

What about combination products in the EU?

In Baltimore, a panel of European regulators and industry representatives discussed streamlining the regulatory pathway for combination products in the EU. The session took place at the AFDO/RAPS Combination Products Summit. Manufacturers selling drug-device combinations into Europe face split jurisdictions today, and the panel debate addressed that structural friction. The takeaway: EU combination-product process reform remains an open agenda item rather than a settled policy.

This briefing draws on the week's top regulatory, biopharma and medtech coverage. Inclusion here does not imply endorsement by Regulatory Focus or RAPS.

via Regulatory Focus (Google News) (Source)

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering companies, deals and strategy in global pharmaceutical industry at PharmInsider.

7 articles

Linked filings

  1. P-6323
  2. K-4971
  3. K-6477
  4. K-7275
  5. K-8919

« Previous filingNext filing »